Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer

Inclusion Criteria:

* written informed concent
* age \> or equal 18 years
* able to comply with the protocol
* histologically or cytologically confirmed, Her-2 negative, adenocarcinoma of the breast with measurable or nonmeasurable metastatic disease, chemotherapy indicated
* ECOG 0-2, life expectancy of over or qual to 12 wks
* prior neo/adjuvant chemotherapy allowed
* prior adjuvant taxane therapy is allowed, DFS\> or equal 6 months
* previous hormonal therapy allowed
* prior RT is allowed as adjuvant setting or to relief of metastatic bone pain, no more than 30% of marrow-bearing bone irradiated
* Adequate haematological function
* adequate liver function total bilirubin \<1.5 x upper limit of normal and AST,ALT \<2.5 x ULN in patients without liver metastases; \<5 x ULN in patients with liver metastases
* adequate renal function serum creatinine \<or equal 1,5x ULN or calculated creatinine clearance \> or equal 50mL/min and urine dipstick for proteinuria \<2+. Patients discovered to have or equal proteinuria or dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate \< or equal 1 g of protein in 24 hours
* INR\<or equal 1.5 and PTT\< or equal 1.5 x ULN within 7 days prior to enrolment. Anticoagulation treatment not allowed
* if female, should not be pregnant or breast-feeding. Women with an intact uterus must have a negative serum pregnancy test within 28 days prior to inclusion into the study

Exclusion Criteria:

* previous chemotherapy for mBC
* radiation therapy for the treatment of metastatic disease within 28 days
* evidence of CNS metastases. If symptomatic, the patient should be scanned within 28 days to enrolment to rule out CNS metastases
* pre-existing peripheral neuropathy NCI CTC-AE grade \> 2 at enrolment
* major surgery, significant traumatic injury within 28 days prior to enrolment or anticipation of the need for major surgery during study treatment
* Minor surgery, including insertion off an indwelling catheter, within 24 hours prior to the first line bevacizumab infusion
* Current or recent(within 10 daÿs of first dose of bevacizumab) use of aspirin (\>325mg/day)
* current or recent (within 10 days of first dose of bevacizumab) use of oral or parenteral anticoagulants or thrombolytic agents.
* history of evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
* uncontrolled hypertension (systolic \>150mmHg and/or diastolic\>100mmHg)
* Clinically significant cardiovascular disease for example CVA, myocardial infarction, unstable angina, congestive heart failure NYHA Class \> or equal II, serious cardiac arrhythmia requiring medication during the study, which might interfere with regularity of the study treatment, or not controlled by medication
* non- healing wound, active peptic ulcer or bone fracture
* history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment
* past of current history (within the last 5 years) of other malignancies except curatively treated basal and squamous cell carcinoma of the skin or in-situ carcinoma of the cervix
* treatment with any other investigational agent, or participation in another clinical drug trial within 28 days prior to enrolment
* evidence of any other disease, neurological, psychiatric or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
* history of thrombotic disorders within last six months